Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Recommendation of “Moderate Buy” by Brokerages

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been given an average rating of “Moderate Buy” by the seventeen research firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $205.6667.

A number of research analysts have commented on the company. JPMorgan Chase & Co. decreased their price objective on Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating on the stock in a report on Monday, October 27th. Truist Financial boosted their target price on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research report on Monday. Wall Street Zen raised shares of Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Robert W. Baird lifted their price objective on shares of Jazz Pharmaceuticals from $160.00 to $209.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 18th. Finally, Royal Bank Of Canada set a $194.00 target price on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, November 17th.

Insiders Place Their Bets

In other news, Director Heather Ann Mcsharry sold 3,415 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $177.78, for a total transaction of $607,118.70. Following the completion of the sale, the director directly owned 20,449 shares in the company, valued at approximately $3,635,423.22. This represents a 14.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 4,660 shares of the stock in a transaction on Friday, December 5th. The stock was sold at an average price of $171.20, for a total value of $797,792.00. Following the sale, the chief accounting officer directly owned 7,012 shares in the company, valued at approximately $1,200,454.40. This trade represents a 39.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 123,791 shares of company stock valued at $21,991,850 in the last quarter. Company insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. EverSource Wealth Advisors LLC increased its holdings in Jazz Pharmaceuticals by 9.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock valued at $130,000 after buying an additional 81 shares during the period. Tectonic Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 1.5% during the 3rd quarter. Tectonic Advisors LLC now owns 5,626 shares of the specialty pharmaceutical company’s stock worth $742,000 after acquiring an additional 82 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Jazz Pharmaceuticals by 0.6% in the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after acquiring an additional 90 shares during the last quarter. Fairbanks Capital Management Inc. raised its position in Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 94 shares in the last quarter. Finally, Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its stake in Jazz Pharmaceuticals by 8.7% during the second quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock worth $133,000 after purchasing an additional 100 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 1.6%

Shares of NASDAQ:JAZZ opened at $163.68 on Tuesday. Jazz Pharmaceuticals has a 12-month low of $95.49 and a 12-month high of $182.99. The business has a 50 day moving average of $164.34 and a 200-day moving average of $138.25. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. The stock has a market cap of $9.95 billion, a PE ratio of -26.97, a P/E/G ratio of 0.75 and a beta of 0.27.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.